Intravenous Pegloticase Market Players:
- Agmen Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioMarin
- Sarepta Therapeutics
- Benitec Biopharma Inc
- Bioblast Pharma
- PTC Therapeutics
- NS Pharma
- Nobel Pharma Co. Ltd
- Santhera Pharmaceuticals
- Pfizer Inc.
- Fibrinogen
- GSK
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of intravenous pegloticase is assessed at USD 4.67 billion.
The global intravenous pegloticase market size surpassed USD 4.14 billion in 2025 and is projected to witness a CAGR of over 14.2%, crossing USD 15.62 billion revenue by 2035.
North America is projected to hold a 28% share by 2035, owing to the rising prevalence of chronic and refractory gout alongside expanding healthcare infrastructure.
Key players in the market include Agmen Inc., BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobel Pharma Co. Ltd, Santhera Pharmaceuticals, Pfizer Inc., Fibrinogen, GSK.
